[ad_1]
In an effort to combat the growing threat posed by antibiotic-resistant bacteria, Australian researchers developed an experimental drug therapy for reconverted Alzheimer’s disease, which successfully eliminated some of Xinhua’s hardest-to-treat superbugs. quoted by Agerpres.
Launched on Thursday, the study, led by researchers from the University of Queensland (UQ), the University of Melbourne and Griffith University in Australia, used a specific property of the PBT2 drug to disrupt the mechanisms responsible for these bacteria’s antibiotic resistance. .
“Led by UQ’s Dr David De Oliveira, our team hypothesized that if this experimental treatment for Alzheimer’s were used to destroy the metals within these bacteria, we would have disrupted their antibiotic resistance mechanisms as well.“, to She said UQ Professor Mark Walker.
“This has been demonstrated in the case of the Alzheimer’s drug – combined with the antibiotic polymyxin – by successfully fighting antibiotic-resistant superbugs such as Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli.“, added the specialist.
The recently discovered use of PBT2 has also raised the hope of bringing back old antibiotics, previously considered ineffective in treating superbug infections.
“Since we have been able to combine it with the polymyxin antibiotic to treat polymyxin-resistant bacteria, we may be able to make other antibiotics effective again in the treatment of infectious diseases.“, to She said Professor Mark von Itzstein of Griffith University.
“This may reiterate, as it were, some of the weapons we thought we had lost in our fight against antibiotic-resistant bacteria.“, He added.
The researchers noted that the treatment based on the combination of polymyxin and PBT2 has also been shown to be effective in animal tests and expressed the hope that the clinical trial will begin in the not too distant future, as PBT2 is already considered safe for use. . to people.
Publisher: Monica Bonea
.
[ad_2]
Source link
